Dafna D Gladman1, Dominique Ibañez, Murray B Urowitz. 1. The University of Toronto Lupus Clinic, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, Ontario, Canada.
Abstract
OBJECTIVE: To describe the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K), a modification of SLEDAI to reflect persistent, active disease in those descriptors that had previously only considered new or recurrent occurrences, and to validate SLEDAI-2K against the original SLEDAI as a predictor for mortality and as a measure of global disease activity in the clinic. METHODS: All visits in our cohort of 960 patients were used to correlate SLEDAI-2K against the original SLEDAI, and the whole cohort was used to validate SLEDAI-2K as a predictor of mortality. A subgroup of 212 patients with SLE followed at the Lupus Clinic who had 5 regular visits, 3-6 months apart, in 1991-93 was also included. An uninvolved clinician evaluated each patient record and assigned a clinical activity level. The SLEDAI score was calculated from the database according to both the original and modified definitions. RESULTS: SLEDAI-2K correlated highly (r = 0.97) with SLEDAI. Both methods for SLEDAI scoring predicted mortality equally (p = 0.0001), and described similarly the range of disease activity as recognized by the clinician. CONCLUSION: SLEDAI-2K, which allows for persistent activity in rash, mucous membranes, alopecia, and proteinuria, is suitable for use in clinical trials and studies of prognosis in SLE.
OBJECTIVE: To describe the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K), a modification of SLEDAI to reflect persistent, active disease in those descriptors that had previously only considered new or recurrent occurrences, and to validate SLEDAI-2K against the original SLEDAI as a predictor for mortality and as a measure of global disease activity in the clinic. METHODS: All visits in our cohort of 960 patients were used to correlate SLEDAI-2K against the original SLEDAI, and the whole cohort was used to validate SLEDAI-2K as a predictor of mortality. A subgroup of 212 patients with SLE followed at the Lupus Clinic who had 5 regular visits, 3-6 months apart, in 1991-93 was also included. An uninvolved clinician evaluated each patient record and assigned a clinical activity level. The SLEDAI score was calculated from the database according to both the original and modified definitions. RESULTS: SLEDAI-2K correlated highly (r = 0.97) with SLEDAI. Both methods for SLEDAI scoring predicted mortality equally (p = 0.0001), and described similarly the range of disease activity as recognized by the clinician. CONCLUSION: SLEDAI-2K, which allows for persistent activity in rash, mucous membranes, alopecia, and proteinuria, is suitable for use in clinical trials and studies of prognosis in SLE.
Authors: Hermine I Brunner; Marisa S Klein-Gitelman; Gloria C Higgins; Sivia K Lapidus; Deborah M Levy; Anne Eberhard; Nora Singer; Judyann C Olson; Karen Onel; Marilynn Punaro; Laura Schanberg; Emily von Scheven; Jun Ying; Edward H Giannini Journal: Arthritis Care Res (Hoboken) Date: 2010-06 Impact factor: 4.794
Authors: M B Urowitz; D Gladman; D Ibañez; S C Bae; J Sanchez-Guerrero; C Gordon; A Clarke; S Bernatsky; P R Fortin; J G Hanly; D J Wallace; D Isenberg; A Rahman; G S Alarcón; J T Merrill; E Ginzler; M Khamashta; O Nived; G Sturfelt; I N Bruce; K Steinsson; S Manzi; R Ramsey-Goldman; M A Dooley; A Zoma; K Kalunian; M Ramos; R F Van Vollenhoven; C Aranow; T Stoll; M Petri; P Maddison Journal: Arthritis Care Res (Hoboken) Date: 2010-06 Impact factor: 4.794
Authors: A Tomin; T Dumych; Y Tolstyak; I Kril; I Mahorivska; E Bila; R Stoika; M Herrmann; Y Kit; R Bilyy Journal: Clin Exp Immunol Date: 2015-01 Impact factor: 4.330
Authors: Carly Skamra; Juanita Romero-Diaz; Alexander Sandhu; QiQuan Huang; Jungwha Lee; William Pearce; David D McPherson; Kim Sutton-Tyrrell; Richard Pope; Rosalind Ramsey-Goldman Journal: Rheumatology (Oxford) Date: 2013-02-04 Impact factor: 7.580
Authors: Lina Wirestam; Helena Enocsson; Thomas Skogh; Leonid Padyukov; Andreas Jönsen; Murray B Urowitz; Dafna D Gladman; Juanita Romero-Diaz; Sang-Cheol Bae; Paul R Fortin; Jorge Sanchez-Guerrero; Ann E Clarke; Sasha Bernatsky; Caroline Gordon; John G Hanly; Daniel Wallace; David A Isenberg; Anisur Rahman; Joan Merrill; Ellen Ginzler; Graciela S Alarcón; W Winn Chatham; Michelle Petri; Munther Khamashta; Cynthia Aranow; Meggan Mackay; Mary Anne Dooley; Susan Manzi; Rosalind Ramsey-Goldman; Ola Nived; Kristjan Steinsson; Asad Zoma; Guillermo Ruiz-Irastorza; Sam Lim; Ken Kalunian; Murat Inanc; Ronald van Vollenhoven; Manuel Ramos-Casals; Diane L Kamen; Søren Jacobsen; Christine Peschken; Anca Askanase; Thomas Stoll; Ian N Bruce; Jonas Wetterö; Christopher Sjöwall Journal: J Rheumatol Date: 2019-01-15 Impact factor: 4.666